Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma

Phase 2

• Conditions: Recurrent or Refractory Primary CNS Lymphoma
• Interventions: Drug: temsirolimus

• Registration Number: NCT00942747
• Lead Sponsor: Charite University, Berlin, Germany

Brief Summary

This is an open-label trial investigating the efficacy of temsirolimus in recurrent or refractory primary CNS lymphoma (PCNSL) after initial chemotherapy with a high-dose methotrexate containing regimen. 37 patients are planned to be treated with weekly infusions of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months. The trial is designed in two stages, if less than one of the first 12 patients responds to treatment, the trial is stopped. In addition to efficacy, safety and penetration of temsirolimus into the cerebrospinal fluid will be investigated.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-07
• Study First Submitted: 2009-07-20
• Study First Submitted QC: 2009-07-20
• Study First Posted: 2009-07-21
• Status Verified: 2013-04
• Last Update Submitted: 2013-04-15
• Last Update Posted: 2013-04-17
• Primary Completion: 2013-12
• Study Completion: 2014-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

• Primary CNS lymphoma diagnosed histologically or by cerebrospinal fluid cytology; absence of systemic lymphoma manifestations
• Relapse or lymphoma progression after/during high-dose methotrexate containing first-line chemotherapy or alternative therapy in the case of contraindications against high-dose methotrexate
• ECOG performance score ≤ 2
• Age ≥18 years and ≤ 75 years
• Life expectancy of at least 3 months
• Absence of active infection
• Negative HIV serology
• Adequate renal function (GFR >30ml/h)
• Adequate bone marrow reserve (neutrophils > 1500/µl, platelets > 80,000/µl)
• Bilirubin <1.5x upper limit of normal (ULN), ALT and AST <3x ULN
• At least 3 weeks interval from prior cytostatic treatment
• Negative pregnancy test
• Patient accessible for treatment and follow-up
• Patient compliance
• Signed informed consent

Exclusion Criteria

• Secondary CNS lymphoma
• Primary intraocular lymphoma
• Patient eligible for high-dose chemotherapy and autologous stem-cell transplantation
• Concurrent treatment within another clinical trial
• Concurrent other malignant disease
• Symptomatic congestive heart failure (≥NYHA II)
• Active or uncontrolled chronic infection
• Severe concomitant disease incompatible with study conduct
• History of cerebral bleeding
• Concomitant treatment with strong CYP3A4/5-inductors or -inhibitors
• Premenopausal women without highly effective contraception (defined as Pearl index <1)
• Pregnant or lactating women
• Refusal to record and pass on pseudonymized disease and treatment related data as part of the treatment protocol
• Concurrent admission to a psychiatric institution by public order

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Temsirolimus	temsirolimus	Weekly IV temsirolimus

Primary Outcome Measures

Name	Time	Method
Overall response rate	Weeks 4, 12, every 12 weeks thereafter

Secondary Outcome Measures

Name	Time	Method
Safety	continuous
Time to progression of disease	Weeks 4, 12, every 12 weeks thereafter or upon clinical suspicion of disease progression
Penetration of temsirolimus into cerebrospinal fluid	Weeks 1, 4 and 12

Trial Locations

Locations (6)

Neurology, Knappschaftskrankenhaus Bochum, Bochum University; 🇩🇪 Bochum, Germany

Hematology, Klinikum Frankfurt/Oder; 🇩🇪 Frankfurt an der Oder, Germany

Klinikum Grosshadern, University Hospital Munich; 🇩🇪 Munich, Germany

Charité Campus Benjamin Franklin; 🇩🇪 Berlin, Germany

Neurology, University Hospital Bonn; 🇩🇪 Bonn, Germany

Hematology, University Hospital Heidelberg; 🇩🇪 Heidelberg, Germany